Bioequivalence Study in Healthy Chinese Subjects Comparing SP-01 (Granisetron Patch) Manufactured at Two Different Sites
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)Drug: SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 66
- Registration Number
- NCT05075876
- Locations
- 🇭🇰
Phase 1 Clinical Trials Centre, The University of Hong Kong, Hong Kong, Hong Kong
A Trial of Episil® Oral Liquid in Cancer Patients Suffering From Chemotherapy- and/or Radiation-induced Oral Mucositis
Not Applicable
Completed
- Conditions
- Chemotherapy- and/or Radiation-induced Oral Mucositis
- Interventions
- Device: Kang SuDevice: episil®
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 60
- Registration Number
- NCT03546985
- Locations
- 🇨🇳
The People's Liberation Army 307 Hospital, Beijing, Beijing, China
🇨🇳Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2
Completed
- Conditions
- Peripheral T-Cell Lymphoma
- Interventions
- Drug: SP-02L (darinaparsin for injection)
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 67
- Registration Number
- NCT02653976
A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting
Phase 3
Completed
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Drug: SP-01 (Granisetron Transdermal Delivery System)
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 313
- Registration Number
- NCT01937156
- Locations
- 🇨🇳
The 81st Hospital of P.L.A., Nanjing, Jiangsu, China
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Phase 1
Completed
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Drug: SP-02L (darinaparsin for injection)
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 6
- Registration Number
- NCT01689220
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1
Completed
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Drug: SP-02L (darinaparsin for injection)
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 17
- Registration Number
- NCT01435863
© Copyright 2025. All Rights Reserved by MedPath